Preclinical Ophthalmic Drug Development Services ace

Ocular Implant Development Services for Drug Delivery

Ocular implants are an effective solution for posterior segment ocular disease. As a full-service ophthalmic product preclinical development CRO, Ace Therapeutics provides one-stop ocular implant development services. Benefiting from our extensive experience in the development of long-acting dosage forms, we provide global customers with customized development strategies based on the type of your drug (small molecule drugs, proteins and biologics, and cell-based implants) into the object designed.

Development of an Ocular Implant Drug Delivery System for Ocular Disease

Advantages of Ocular Implant

Treatment of posterior segment diseases delivers effective doses of drugs to the vitreous, retina, and choroid. Traditional treatment methods: 1) Topical application of drugs due to low permeability of extra-orbital tissues leads to poor absorption; 2) Systemic administration due to the blood-retinal barrier limits the diffusion of drugs from systemic blood to the posterior segment; 3) Intraocular injection due to the rapid flow of the posterior segment of the eye. The blood supply results in a drug with extremely high clearance and low bioavailability. Ocular implants are made of different biocompatible, biodegradable, or non-biodegradable polymers, as an alternative treatment for posterior eye diseases, which can provide long-term drug release for posterior eye diseases. Enables longer-lasting, highly localized drug delivery with more accurate drug concentrations and fewer side effects than any other route of administration.

Fig. 1. Development timeline for intraocular implants. (Adrianto MF, et al., 2022)

What Is Ace Therapeutics Doing for Ocular Drug Delivery System Development?

Ocular implants offer a viable option for the treatment of ocular diseases. Ace Therapeutics is committed to providing an unparalleled solution to eye disease research for global customers. You will benefit from our researchers' rich experience in long-acting dosage forms and advanced technical equipment to promote your project implementation. We develop our overall strategy based on the type of drug, including, but not limited to small molecule drugs, proteins, biologics, and cell-based implants.

One-stop Ocular Implant Drug Delivery System Development Service for Ocular Disease

Key to the development of ocular implants is the choice of polymer and sterility assurance. Ace Therapeutics has developed a highly standardized ophthalmic product development process to serve global customers. We provide one-stop eye implant development services for global customers, including but not limited to:

Polymer selection

Biodegradable polymer
Non-degradable biopolymer.

Biocompatibility testing
In vitro dissolution assay
Ocular pharmacodynamic assessment
Implantation method

Intravitreal injection
Subconjunctival administration
Intracameral implantation via an incision

Application Fields

Retinitis
Uveitis
Diabetic Retinopathy (DR)
Proliferative Vitreoretinopathy
Post Cataract Disease

Our Capabilities

Additionally, Ace Therapeutics offers the following other ocular delivery systems that may be of interest to you, ask our scientists for details.

As a contract provider of solutions for ocular diseases, in order to better understand unmet needs, successful delivery of ocular drug delivery systems. Ace Therapeutics provides one-stop ocular implant development services. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Cao Y, Samy KE, Bernards DA, et al. Recent advances in intraocular sustained-release drug delivery devices. Drug Discov Today. 2019 Aug;24(8):1694-1700.
Pons-Faudoa FP, Ballerini A, Sakamoto J, et al. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices. 2019 May 18;21(2):47.
Adrianto MF, Annuryanti F, Wilson CG. et al. In vitro dissolution testing models of ocular implants for posterior segment drug delivery. Drug Deliv. and Transl. Res. 2022;(12)1355-1375.

For Research Use Only.

Get in Touch